Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.
Age ≥18 years
Morbid obesity (BMI ≥40 kg/m² or BMI ≥35 kg/m² with obesity-related comorbidities)
Newly prescribed GLP-1 receptor agonist therapy
Ability and willingness to provide written informed consent
Inflammatory bowel disease
Perianal Crohn's disease
History of anorectal malignancy
Previous pelvic radiotherapy